Compare Invesco S&P 500 High Div Low Volatility ETF (SPHD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 High Div Low Volatility ETF vs TG Therapeutics Inc — how do they compare? Invesco S&P 500 High Div Low Volatility ETF trades at $52.67, while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SPHD | TGTX | |
|---|---|---|
52-Week High | $53.55 | $59.06 |
52-Week Low | $46.96 | $26.94 |
Market Cap | — | $7.64B |
Sector | — | Health |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPHD trades at $52.47, showing minimal daily movement with a 0.11% gain. The ETF maintains a bullish technical outlook with strong moving average signals and key support at $52. Recent dividend payments of $0.21 demonstrate consistent income generation, while news coverage highlights growing investor interest in dividend and low-volatility strategies amid market uncertainty.
The ETF's focus on high dividend yield with low volatility positions it well for income-seeking investors, though the absence of fundamental ratios limits traditional valuation analysis. Market sentiment appears favorable as investors shift toward defensive strategies, but reliance on dividend sustainability and market volatility patterns present ongoing considerations.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
